Novo Nordisk Will Sell An Unbranded Version of Tresiba in the U.S.

Sometimes communicating the right message to the right party at the right time may result in a pleasantly unexpected thing happening!During this year ' s EASD which took place in Stockholm, Sweden (a beautiful city I ' ve visited more than a few times over the years), at the end of a Live Tweet event with Novo Nordisk Live@NovoNordiskLive, I shared a few thoughts which had been bothering me about Novo Nordisk ' s commitment to its U.S. unbranded insulin strategy (I described its commitment as " half-hearted " ), and I did so by sharing several slide images which I got directly from Novo Nordisk ' s quarterly investor presentations and the company ' s 2021 annual report.        Frankly, I did so because I felt as if the Danish company was simultaneously boasting to company investors about how much " assistance " the company ' s affordability options in the U.S. were providing, while also doing so for essentially a single product (unless you include its pre-mixed insulin varieties which are not very big sellers anyway). In my mind, that was hardly a corporate commitment to the company ' s unbranded insulin strategy.And yet, at the same time, Novo Nordisk is one of the biggest contributors to the PBM rebate problem responsible for runaway U.S. insulin prices in the first place. By last disclosure, Novo Nordisk revealed that the company was paying PBM ' s 74% rebates of its gross U.S. sales in order to keep competing products off many insur...
Source: Scott's Web Log - Category: Endocrinology Tags: authorized generic insulin analogs 2022 authorized generics Inc. Novo Nordisk Pharma unbranded insulin Source Type: blogs